
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic is positioned for strong growth, with expectations of 5-7% organic revenue growth driven by robust procedure volume increases, new product launches, and strategic acquisitions. The company’s ongoing improvements in Diagnostics and Breast Health segments may lead to accelerated revenue growth in the high-single digits, with potential for enhanced operating margins and significant earnings growth of 8-12%. Additionally, Hologic's strong balance sheet and low leverage provide a solid foundation for continued margin expansion and favorable business trends moving forward.
Bears say
Hologic's stock faces a negative outlook primarily due to anticipated revenue growth slowing to low-single digits (1-4%), predominantly attributed to weakness in its Diagnostics and Breast Health segments. The company's performance has been disappointing, with only 9.4% and 4.4% returns over the past three and five years, respectively, and further growth potential appears limited amid softening demand and increased competition. Additionally, the challenges posed by a weak global economy, integration difficulties from recent acquisitions, and the likelihood of stagnating operating margins indicate significant risk to Hologic's future earnings potential.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares